Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.

Tisi MC, Paolini R, Piazza F, Ravelli E, Tecchio C, Sartori R, Famengo B, D'Amore ESG, Carli G, Perbellini O, Di Bona E, Ruggeri M, Visco C.

Am J Hematol. 2018 Sep 5. doi: 10.1002/ajh.25278. [Epub ahead of print] No abstract available.

PMID:
30184246
2.

Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases.

Visentin A, Campello E, Scomazzon E, Spiezia L, Imbergamo S, Pravato S, Piazza F, Semenzato G, Simioni P, Trentin L.

Hematol Oncol. 2018 Aug 15. doi: 10.1002/hon.2545. [Epub ahead of print] No abstract available.

PMID:
30110712
3.

Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission.

Kostic I, Ruiz M, Branca A, Nabergoj M, Piazza F, Semenzato G, Gurrieri C, Briani C.

J Neurol Sci. 2018 Sep 15;392:63-64. doi: 10.1016/j.jns.2018.06.029. Epub 2018 Jun 30. No abstract available.

PMID:
30049661
4.

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.

Visentin A, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Bonaldi L, Pizzi M, Vio S, Gregianin M, Burei M, Facco M, Semenzato G, Piazza F, Trentin L.

Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15440. [Epub ahead of print] No abstract available.

PMID:
29974955
5.

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation.

Barilà G, Teramo A, Calabretto G, Ercolin C, Boscaro E, Trimarco V, Carraro S, Leoncin M, Vicenzetto C, Cabrelle A, Facco M, Piazza F, Semenzato G, Zambello R.

Blood Cancer J. 2018 Jun 5;8(6):51. doi: 10.1038/s41408-018-0088-1. No abstract available.

6.

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.

Manni S, Carrino M, Semenzato G, Piazza F.

Int J Mol Sci. 2018 May 18;19(5). pii: E1512. doi: 10.3390/ijms19051512. Review.

7.

Hopping in the Crowd to Unveil Network Topology.

Asllani M, Carletti T, Di Patti F, Fanelli D, Piazza F.

Phys Rev Lett. 2018 Apr 13;120(15):158301. doi: 10.1103/PhysRevLett.120.158301.

PMID:
29756854
8.

Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.

Scapinello G, Pizzi M, Vio S, Nabergoj M, Visentin A, Martines A, Bonaldi L, Trentin L, Semenzato G, Piazza F.

Ann Hematol. 2018 Oct;97(10):2001-2003. doi: 10.1007/s00277-018-3351-4. Epub 2018 May 4. No abstract available.

PMID:
29728736
9.

Driven-Dissipative Supersolid in a Ring Cavity.

Mivehvar F, Ostermann S, Piazza F, Ritsch H.

Phys Rev Lett. 2018 Mar 23;120(12):123601. doi: 10.1103/PhysRevLett.120.123601.

PMID:
29694105
10.

Correction to: Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.

Manni S, Carrino M, Piazza F.

J Hematol Oncol. 2018 Apr 5;11(1):51. doi: 10.1186/s13045-018-0588-2.

11.

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.

Canovas Nunes S, Manzoni M, Pizzi M, Mandato E, Carrino M, Quotti Tubi L, Zambello R, Adami F, Visentin A, Barilà G, Trentin L, Manni S, Neri A, Semenzato G, Piazza F.

Blood Cancer J. 2018 Feb 13;8(2):20. doi: 10.1038/s41408-018-0053-z.

12.

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases.

Visentin A, Imbergamo S, Frezzato F, Pizzi M, Bertorelle R, Scomazzon E, Berno T, Riva M, Piva E, Facco M, Piazza F, Semenzato G, Trentin L.

Oncotarget. 2017 Sep 28;8(66):110727-110731. doi: 10.18632/oncotarget.21304. eCollection 2017 Dec 15.

13.

STAT3 mutation impacts biological and clinical features of T-LGL leukemia.

Teramo A, Barilà G, Calabretto G, Ercolin C, Lamy T, Moignet A, Roussel M, Pastoret C, Leoncin M, Gattazzo C, Cabrelle A, Boscaro E, Teolato S, Pagnin E, Berno T, De March E, Facco M, Piazza F, Trentin L, Semenzato G, Zambello R.

Oncotarget. 2017 Jun 27;8(37):61876-61889. doi: 10.18632/oncotarget.18711. eCollection 2017 Sep 22.

14.

Exciton transport in the PE545 complex: insight from atomistic QM/MM-based quantum master equations and elastic network models.

Pouyandeh S, Iubini S, Jurinovich S, Omar Y, Mennucci B, Piazza F.

Phys Biol. 2017 Nov 16;14(6):066001. doi: 10.1088/1478-3975/aa90ea.

PMID:
28976354
15.

Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.

Visentin A, Briani C, Imbergamo S, Frezzato F, Angelini A, Fedrigo M, Cacciavillani M, Altinier S, Piazza F, Semenzato G, Adami F, Trentin L.

Hematol Oncol. 2018 Feb;36(1):366-369. doi: 10.1002/hon.2480. Epub 2017 Oct 3.

PMID:
28971495
16.

Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.

Manni S, Carrino M, Piazza F.

J Hematol Oncol. 2017 Oct 2;10(1):157. doi: 10.1186/s13045-017-0529-5. Review. Erratum in: J Hematol Oncol. 2018 Apr 5;11(1):51.

17.

Disorder-Driven Density and Spin Self-Ordering of a Bose-Einstein Condensate in a Cavity.

Mivehvar F, Piazza F, Ritsch H.

Phys Rev Lett. 2017 Aug 11;119(6):063602. doi: 10.1103/PhysRevLett.119.063602. Epub 2017 Aug 9.

PMID:
28949625
18.

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.

Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D, Accardi F, Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N.

Oncotarget. 2017 May 23;8(32):53053-53067. doi: 10.18632/oncotarget.18085. eCollection 2017 Aug 8.

19.

A Combined One-Class SVM and Template-Matching Approach for User-Aided Human Fall Detection by Means of Floor Acoustic Features.

Droghini D, Ferretti D, Principi E, Squartini S, Piazza F.

Comput Intell Neurosci. 2017;2017:1512670. doi: 10.1155/2017/1512670. Epub 2017 May 30.

20.

Aberrant expression of CD10 and BCL6 in mantle cell lymphoma.

Pizzi M, Agostinelli C, Righi S, Gazzola A, Mannu C, Galuppini F, Fassan M, Visentin A, Piazza F, Semenzato GC, Rugge M, Sabattini E.

Histopathology. 2017 Nov;71(5):769-777. doi: 10.1111/his.13286. Epub 2017 Aug 8.

PMID:
28628241

Supplemental Content

Loading ...
Support Center